Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080035 | 0.80 | PPM1D (0.33) | — | |
| SCHEMBL17924750 | 0.74 | CNR2 (0.32) | LMNAPOLBTSHRCYP1A2ALDH1A1 | |
| SCHEMBL17924751 | 0.74 | CNR2 (0.32) | LMNAPOLBTSHRCYP1A2ALDH1A1 | |
| SCHEMBL17924754 | 0.74 | CNR2 (0.32) | LMNAPOLBTSHRCYP1A2ALDH1A1 | |
| SCHEMBL17686382 | 0.68 | KDM4E (0.37) | LMNAGAACYP1A2EPHX2ALDH1A1 | |
| SCHEMBL23777333 | 0.66 | — | — | |
| SCHEMBL15189250 | 0.64 | MEN1 (0.51) | MAPTLMNAEPHX2ALDH1A1 | |
| SCHEMBL16538439 | 0.64 | SMN1; SMN2 (0.34) | TSHR | |
| SCHEMBL25243556 | 0.63 | — | — | |
| SCHEMBL25251818 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906532-B2 | Antiserotonine agents; gastrointestinal disorders; irritable bowel syndrome; central nervous system disorders; Alzheimer's disease; cognition activators; analgesics; cardiovascular disorders; antidiabetic agents; sleep disorders | PFIZER INC. (US) | 2011-03-15 | — | — | US | disclosed |